GHK-Cu: What It Is, What the Research Shows, and How It Is Regulated in Australia

Published September 2026

GHK-Cu is a copper-binding complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK). Research into GHK-Cu has examined biological processes including skin biology, inflammation and tissue-related processes, although much of the evidence remains preclinical rather than being derived from large, controlled clinical trials in humans. (Pickart & Margolina, 2018)

GHK-Cu is also used as an ingredient in some topical cosmetic products. The presence of GHK-Cu in a cosmetic product does not mean that every product containing GHK-Cu has the same regulatory classification. In Australia, whether a product is a cosmetic or a therapeutic good can depend on factors including its composition, claims, intended use, route of administration and overall presentation. (Therapeutic Goods Administration [TGA], 2026a)

What Is GHK-Cu?

GHK-Cu is a copper-binding complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK). Research into GHK-Cu has examined biological processes including skin biology, inflammation and tissue-related processes, although much of the evidence remains preclinical rather than being derived from large, controlled clinical trials in humans. (Pickart & Margolina, 2018)

GHK-Cu is also used as an ingredient in some topical cosmetic products. The presence of GHK-Cu in a cosmetic product does not mean that every product containing GHK-Cu has the same regulatory classification. In Australia, whether a product is a cosmetic or a therapeutic good can depend on factors including its composition, claims, intended use, route of administration and overall presentation. (Therapeutic Goods Administration [TGA], 2026a)

What Does the Research Show?

GHK-Cu has been investigated in laboratory and preclinical research for potential biological effects involving skin, tissue repair, inflammation and related cellular processes. These studies provide information about biological mechanisms and areas for further investigation, but preclinical findings do not by themselves establish the safety or effectiveness of a particular product in humans. (Pickart & Margolina, 2018)

The available evidence should therefore be considered according to the type of research from which it comes. Laboratory and animal studies can help researchers investigate mechanisms and potential biological activity, while clinical trials in humans are required to establish whether a particular intervention is safe and effective for a particular intended use. (Therapeutic Goods Administration [TGA], 2026b)

Claims that GHK-Cu can provide particular therapeutic outcomes should not be inferred solely from laboratory or animal research. The strength of evidence depends on the specific use being investigated, the formulation, route of administration, dose and quality of the available human evidence. (Therapeutic Goods Administration [TGA], 2026b)

GHK-Cu in Cosmetics and Therapeutic Goods

GHK-Cu can appear in products that fall within different regulatory categories. A topical product presented for cosmetic purposes may be regulated as a cosmetic, while a product making therapeutic claims or otherwise meeting the definition of a therapeutic good may fall within the therapeutic-goods regulatory framework. (Therapeutic Goods Administration [TGA], 2026a)

The TGA explains that classification cannot necessarily be determined from an ingredient name alone. The overall circumstances of the product are relevant, including its claims, composition, use and presentation. This means that the fact an ingredient is permitted or used in a cosmetic product does not automatically establish the regulatory status of another product containing the same ingredient. (Therapeutic Goods Administration [TGA], 2026a)

This distinction is particularly important when discussing peptide-containing skincare products alongside products presented for therapeutic purposes. Cosmetic use and therapeutic use should not be treated as interchangeable categories simply because they contain the same named ingredient. (Therapeutic Goods Administration [TGA], 2026a)

How Is GHK-Cu Regulated in Australia?

The Australian regulatory framework distinguishes between a substance or ingredient and a particular finished therapeutic product. The Australian Register of Therapeutic Goods (ARTG) is the register of therapeutic goods that have been included for lawful supply in Australia, subject to applicable legislative requirements and exemptions. (Therapeutic Goods Administration [TGA], 2026c)

The TGA’s April 2026 safety alert identifies GHK-Cu among examples of unapproved peptide products that may be supplied, compounded, imported or promoted in Australia. The TGA states that unapproved therapeutic goods have not been evaluated by the TGA for safety, quality and effectiveness in the same way as products that have undergone the applicable Australian regulatory assessment process. (Therapeutic Goods Administration [TGA], 2026d)

This does not mean that every product containing the words “GHK-Cu” has an identical regulatory status. The status of a particular product needs to be considered according to the product itself, including its formulation, claims, intended purpose, route of administration and applicable Australian regulatory requirements. (Therapeutic Goods Administration [TGA], 2026a); (Therapeutic Goods Administration [TGA], 2026c)

What About Compounded Medicines?

Compounding and ARTG registration are separate regulatory concepts. The TGA recognises specific circumstances in which compounded medicines may be manufactured or supplied under applicable exemptions and conditions, but a compounded medicine is not thereby equivalent to an ARTG-registered medicine. (Therapeutic Goods Administration [TGA], 2026e)

The TGA also states that compounded medicines are generally prohibited from being advertised to the public unless an applicable exemption or government requirement applies. Advertising requirements therefore need to be considered separately from whether a particular compounding activity may be permitted under the applicable framework. (Therapeutic Goods Administration [TGA], 2026e)

The regulatory position concerning unapproved peptide products has received increased attention from the TGA during 2026. The TGA has identified unapproved peptide products as a compliance priority and has published specific information concerning their advertising, importation, supply and compounding. (Therapeutic Goods Administration [TGA], 2026d); (Therapeutic Goods Administration [TGA], 2026f)

Advertising and GHK-Cu

The TGA’s advertising framework requires the first question to be whether a therapeutic good can legally be advertised to the public. Where public advertising is permitted, advertising must also comply with requirements concerning accuracy, substantiation, balance, scientific evidence and the overall presentation of the advertisement. (Therapeutic Goods Administration, 2023)

The TGA’s consumer advertising checklist states that an assessment considers the total presentation and context of an advertisement, including the target audience and the likely impact on a reasonable consumer. A disclaimer therefore needs to be considered as part of the overall presentation rather than as a substitute for compliance with the advertising requirements. (Therapeutic Goods Administration, 2023)

Scientific information should also be presented in a way that is consistent with the body of available scientific or clinical evidence. Where research is referenced in advertising, the TGA checklist states that relevant research should be identified and cited so consumers can access the underlying material. (Therapeutic Goods Administration, 2023)

For this reason, educational information about GHK-Cu should distinguish clearly between established regulatory facts, scientific research findings and areas where evidence remains limited. Research findings should not be presented as guarantees of safety, effectiveness or therapeutic outcomes. (Therapeutic Goods Administration, 2023)

Frequently Asked Questions

Is GHK-Cu a cosmetic or a medicine?

GHK-Cu itself should not automatically be classified as either a cosmetic or a medicine simply from the name of the ingredient. The regulatory classification of a particular product can depend on factors including its composition, claims, intended use, route of administration and overall presentation. (Therapeutic Goods Administration [TGA], 2026a)

Is GHK-Cu TGA approved?

A GHK-Cu-containing product should not be described as “TGA approved” unless there is a specific applicable Australian regulatory authorisation or ARTG entry supporting that statement. The TGA has identified GHK-Cu among examples of unapproved peptide products. (Therapeutic Goods Administration [TGA], 2026c); (Therapeutic Goods Administration [TGA], 2026d)

Does research prove that GHK-Cu is effective in humans?

No general conclusion about the effectiveness of GHK-Cu for a particular therapeutic purpose can be drawn solely from laboratory or animal research. The type, quality and relevance of the available evidence need to be considered for the particular use being discussed. (Pickart & Margolina, 2018); (Therapeutic Goods Administration [TGA], 2026b)

Why is GHK-Cu found in some skincare products?

GHK-Cu is used as an ingredient in some cosmetic products. Whether a particular product is regulated as a cosmetic depends on the product’s circumstances, including its claims, composition, intended use and presentation. The presence of an ingredient in a cosmetic product does not automatically determine the regulatory classification of another product containing that ingredient. (Therapeutic Goods Administration [TGA], 2026a)

Does compounding mean that GHK-Cu is TGA approved?

No. Compounding and ARTG registration are separate concepts. The existence of a lawful compounding pathway in particular circumstances does not mean that the resulting compounded preparation has been evaluated by the TGA and included in the ARTG as an approved medicine. (Therapeutic Goods Administration [TGA], 2026c); (Therapeutic Goods Administration [TGA], 2026e)

Key Takeaways

GHK-Cu is a copper-binding peptide complex that has been investigated in laboratory and preclinical research and is also used in some cosmetic products. The available research should be distinguished from evidence generated through appropriately designed clinical studies in humans. (Pickart & Margolina, 2018)

The Australian regulatory status of a particular GHK-Cu-containing product depends on the product and its circumstances, including its claims, composition, intended purpose, route of administration and presentation. GHK-Cu has also been identified by the TGA among examples of unapproved peptide products that are subject to the current Australian regulatory framework. (Therapeutic Goods Administration [TGA], 2026a); (Therapeutic Goods Administration [TGA], 2026d)

Cosmetic use, therapeutic use, ARTG registration and compounding are separate regulatory concepts. The presence of GHK-Cu in a cosmetic product does not establish that another GHK-Cu-containing product is a cosmetic, an approved medicine or otherwise authorised for therapeutic use. (Therapeutic Goods Administration [TGA], 2026a); (Therapeutic Goods Administration [TGA], 2026c); (Therapeutic Goods Administration [TGA], 2026e)

Scientific research and regulatory approval should therefore be considered separately. Preclinical research can provide useful information about biological mechanisms and potential areas of investigation, but it does not establish that a particular GHK-Cu product is safe, effective or approved for a particular therapeutic purpose in humans. (Therapeutic Goods Administration [TGA], 2026b); (Therapeutic Goods Administration [TGA], 2026d)

Disclaimer

This article is provided for general educational and regulatory information only. It is not medical advice and does not constitute an endorsement, recommendation or representation that any GHK-Cu-containing product is safe, effective, approved or suitable for any particular purpose. (Therapeutic Goods Administration, 2023)

The regulatory status of a particular product depends on the circumstances of that product and the requirements that apply under Australian therapeutic-goods legislation. Where the classification or advertising status of a particular product is uncertain, appropriate professional or legal advice should be obtained. (Therapeutic Goods Administration [TGA], 2026a); (Therapeutic Goods Administration [TGA], 2026e)

References

1. Pickart, L. & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data, International Journal of Molecular Sciences, 19(7), 1987. doi:10.3390/ijms19071987. PMID: 29986520.
2. Therapeutic Goods Administration (2023). Advertising compliance self-assessment checklist — Consumer advertising.
3. Therapeutic Goods Administration (2026a). Determining if your product is a cosmetic or a therapeutic good.
4. Therapeutic Goods Administration (2026b). What are ‘therapeutic goods’?
5. Therapeutic Goods Administration (2026c). About the Australian Register of Therapeutic Goods (ARTG).
6. Therapeutic Goods Administration (2026d). Understanding your responsibilities when importing, compounding and supplying unapproved peptide products.
7. Therapeutic Goods Administration (2026e). Manufacturing, supplying and advertising compounded medicines lawfully.
8. Therapeutic Goods Administration (2026f). Unapproved peptide product promoters and suppliers are put on notice.

Related reading

• Approved vs Unapproved Therapeutic Goods: What Is the Difference?
• What Is the ARTG?
• What Is a Compounded Medicine?
• Doctor-Prescribed Peptides in Australia: What the New Ahpra Guidance Says